Neuronetics faces Class 2 NeuroStar recall and analysts rate Neuronetics stock Moderate Buy

Published on 10/18/2026 at 13:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue reached USD 41.57 million versus USD 40.17 million consensus. Five brokerages set a Moderate Buy consensus and USD 4.67 average target for Neuronetics stock.

Events and operating figures

FDA listed a Class 2 NeuroStar recall on October 9, 2026.
Second-quarter revenue reached USD 41.57 million versus USD 40.17 million consensus.
Neuronetics is scheduled to report third-quarter results on November 3, 2026.

STIM, US64131A1051, Illustration mit AI erstellt.

Neuronetics faces a Class 2 NeuroStar recall listed on October 9, 2026, while five brokerages held a Moderate Buy consensus for Neuronetics stock on October 6, 2026, according to FDA and MarketBeat. The recall adds a product-quality issue to a company picture that also includes improving quarterly revenue.

Three events shape the picture

On September 22, 2026, Neuronetics announced an EHR integration linking its TrakStar platform with AdvancedMD, a system used by more than 65,000 practitioners across 13,000 independent practices, as Mobile Health Times reported. On October 6, 2026, MarketBeat cited five brokerages, including four buy ratings and one sell rating, with an average 12-month target of USD 4.67. On October 9, 2026, the FDA classified the NeuroStar recall as Class 2 and described cable and coil inspections with replacement work for affected equipment.

What dates matter next?

MarketBeat lists November 3, 2026, before the market opens, as the estimated reporting date for third-quarter results, with an 8:30 a.m. ET conference call. The EHR integration is scheduled to become available in the fourth quarter of 2026, according to Mobile Health Times.

Revenue gives the recall context

Neuronetics generated USD 41.57 million of revenue in the second quarter of 2026, compared with USD 40.17 million consensus, while adjusted loss per share was USD 0.05 against a USD 0.12 consensus loss, according to MarketBeat. The revenue comparison shows operating demand above expectations, but the Class 2 recall puts execution and service response alongside the growth metric. The company says its NeuroStar platform has delivered more than 4.8 million treatment sessions, according to its investor-relations profile.

Market value and next results

Neuronetics had a market capitalization of USD 143.6 million and a 52-week range of USD 0.80 to USD 3.44 as of October 16, 2026. The next results update will show whether the revenue trajectory and the equipment response develop in parallel. The further course of trading is shown by the continuously updated real-time quote of Neuronetics stock.